Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).

Rossella Elena NappiKimball A JohnsonPetra StuteMartin BloggMarci EnglishAntonia MorgaLudmila ScrineEmad SiddiquiFaith D Ottery

Published in: Menopause (New York, N.Y.) (2024)

Fezolinetant was associated with significantly higher within-patient clinically meaningful improvement in important PRO, including VMS frequency, PROMIS SD SF 8b Total Score, MENQoL Total Score, and MENQoL VMS Domain Score.

Keyphrases

case report
electronic health record
clinical trial
randomized controlled trial
depressive symptoms
open label